HealthLeaders Media January 11, 2023
The 340B program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations and other covered entities at significantly reduced prices.
KEY TAKEAWAYS
– The Supreme Court unanimously ruled that cuts to hospital reimbursement under the 340B drug discount program were unlawful.
– CMS solidified the payment policy for 2023 of average sales price of 6% for drugs and biologicals acquired through the 340B program because of that unanimous Supreme Court decision.
– Leaders agree they will continue to watch what happens with 340B payments as they are a life line for most orginizations.
340B payments are a lifeline for some organizations, so when payments were previously cut, hospital groups were not happy, to say the least.
What...
Today's Sponsors
Today's Sponsor